Generic and biosimilar medicines: quid?

Generic and biosimilar medicines: quid?

Authors

  • Steven Simoens Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

DOI:

https://doi.org/10.7175/fe.v13i3S.448

Keywords:

Generic medicine, Biosimilars

Abstract

Once intellectual property protection, data and marketing exclusivity of reference medicines have expired, generic medicines and biosimilar medicines can enter the off-patent market. This market entry is conditional on the approval of marketing authorization, pricing and reimbursement. Given that there tends to be confusion surrounding generic and biosimilar medicines, this Editorial introduces basic concepts related to generic and biosimilar medicines and presents the different studies and articles included in this supplement dedicated to generic and biosimilar medicines.

Downloads

Published

2012-12-05

How to Cite

Simoens, S. (2012). Generic and biosimilar medicines: quid?. Farmeconomia. Health Economics and Therapeutic Pathways, 13(3S), 3–4. https://doi.org/10.7175/fe.v13i3S.448

Issue

Section

Editorial

Similar Articles

<< < 7 8 9 10 11 12 13 > >> 

You may also start an advanced similarity search for this article.

Loading...